

*B condid.*

- (c) a sulfonylurea;
- (d) a biguanide; and
- (e) an alpha-glucosidase inhibitor.]



*Sub C 27.* (Amended) A method as claimed in claim 1 including adding a pharmaceutical carrier to the therapeutically effective amount of the anti-diabetic agent [drug].

*B 2* (Amended) A composition for the treatment of diabetes mellitus comprising:

- (a) a therapeutic amount of an insulin sensitizer; and
- (b) a therapeutic amount of an anti-diabetic agent. [a drug selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.]

Please add the following claims:

*30. 20* A method as claimed in claim ~~1~~, wherein the anti-diabetic agent is selected from the group consisting of:

- (a) an orally ingestible insulin;
- (b) an injectible insulin;
- (c) a sulfonylurea;
- (d) a biguanide; and
- (e) an alpha-glucosidase inhibitor.

*31. 21* A composition as claimed in claim ~~8~~, wherein the anti-diabetic agent is selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

*32. 22* A composition as claimed in claim ~~81~~, wherein the anti-diabetic agent is

insulin.

*34* 33. A composition as claimed in claim *32*, wherein the insulin is injectible insulin.

*34* 34. A method for the treatment of diabetes mellitus comprising administering to a person afflicted with diabetes mellitus a therapeutic amount of an insulin sensitizer with a therapeutic amount of an orally ingestible anti-diabetic agent, wherein

(1) the insulin sensitizer is selected from the group consisting of: BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411, and wherein

(2) the anti-diabetic agent is selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

*Donald* 35 34. The method of claim *34*, wherein the insulin sensitizer is V-411.

*23* 36. The method of claim *34*, wherein the anti-diabetic agent is an orally ingestible anti-diabetic agent.

37. The method of claim *36*, wherein the anti-diabetic agent is a sulfonylurea.

*24* 38. The method of claim *35* wherein the anti-diabetic agent is an orally ingestible insulin.